Although studies focusing on the effects of anti-TNF-α therapy on bone metabolism in IBD are limited, it was observed that IFX treatment induced beneficial effects on bone metabolism in IBD patients [23,24], which suggests that monoclonal antibodies constitute an important factor in the treatment of osteoporosis. The gene discussed is TNF; the disease is inflammatory bowel disease.